Can a stem cell spray stop radiation mouth pain?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically or cytologically confirmed malignant tumor of the head and neck; 2. Age 18-75 years; 3. Scheduled to receive radical radiotherapy with a total planned dose of ≥60 Gy, with radiation fields including the oral cavity and/or oropharynx; 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and a life expectancy of ≥6 months. 5. White blood cell≥3.0×10\^9/L, hemoglobin≥ 90 g/L, platelet (PLT)≥ 100x10\^9/ L 6. Transaminases≤2.5 times the upper limit of normal, total bilirubin ≤1.5 times the upper limit of normal; 7. Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min; 8. Cardiac: Electrocardiogram (ECG) without clinically significant abnormalities; 9. Intact oral mucosa before initiation of radiotherapy. Absence of active oral infections or severe periodontal disease before initiation of radiotherapy; 10. Signed informed consent form. Exclusion Criteria: 1. Previous radiotherapy to the head and neck region; 2. Head and neck surgery within the preceding 4 weeks; 3. Current participation in another clinical trial, or participation in another interventional study within the past 4 weeks; 4. Significant cardiovascular disease, including unstable angina, myocardial infarction within the past 6 months, severe arrhythmia, or heart failure (NYHA Class III-IV); 5. Severe hepatic or renal dysfunction, such as cirrhosis or chronic renal insufficiency (creatinine clearance \<30 mL/min); 6. Active systemic infection requiring antimicrobial therapy; 7. Autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis) requiring ongoing immunosuppressive treatment; 8. Severe psychiatric disorders that may impair the ability to provide informed consent or adhere to the study protocol; 9. Using other oral mucosal protective agents or anti-inflammatory medications that cannot be discontinued. Long-term use of immunosuppressants or corticosteroids at a prednisone-equivalent dose \>10 mg/day; 10. Individuals unable to comprehend the study requirements or comply with study procedures; 11. Any other condition that, in the judgment of the investigator, would render the patient unsuitable for participation in the study.